Related Experiment Video
Updated: Feb 22, 2026
Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study
Published on: August 15, 2025
An epileptologist's view: Seizure-related outcomes after radiofrequency ablation for mesial temporal lobe epilepsy
Zdeněk Vojtěch1, Michaela Stará1
1Na Homolce Hospital Epilepsy Center, Prague, Czech Republic.
Abstract:
In this article, we provide an overview of the reasons for the introduction of less invasive treatment modalities in the management of intractable mesial temporal lobe epilepsy (mTLE). We summarize our published research on stereotactic amygdalohippocampectomy (SAHE) and recalculate our data for the patients' last visit. In our previous work, we found that patients achieved long-term seizure-free outcomes in 70.5%. Re-analysis of results in a subgroup of patient who were diagnosed and followed-up at Epilepsy Center, Na Homolce Hospital, Prague, indicate that these outcomes are durable. Re-treatment in treatment failures was successful in all cases. The discussion compares novel treatment options and defines the place of SAHE among them.
Insights
Stereotactic amygdalohippocampectomy (SAHE) offers durable, long-term seizure freedom for intractable mesial temporal lobe epilepsy (mTLE). Retreatment for failures proved successful, highlighting SAHE
Area of Science:
- Neurosurgery
- Epileptology
- Neurology
Background:
- Intractable mesial temporal lobe epilepsy (mTLE) poses significant management challenges.
- Less invasive treatment modalities are increasingly explored for mTLE.
- Stereotactic amygdalohippocampectomy (SAHE) is one such approach.
Purpose of the Study:
- To provide an overview of less invasive treatments for mTLE.
- To summarize and re-analyze long-term outcomes of SAHE.
- To compare SAHE with other novel treatment options.
Main Methods:
- Review of published research on SAHE.
- Recalculation of patient data for last visit.
- Analysis of outcomes in a specific patient subgroup.
Main Results:
- Previous studies reported 70.5% long-term seizure-free outcomes with SAHE.
- Re-analysis confirms the durability of these seizure-free outcomes.
- All cases of treatment failure were successfully retreated.
Conclusions:
- SAHE provides durable seizure control for intractable mTLE.
- SAHE is a viable and effective option among novel epilepsy treatments.
- Further comparison with emerging therapies is warranted.
More Related Videos
09:32Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
Published on: December 18, 2016
05:54Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note
Published on: June 13, 2016
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:30Electroconvulsive Therapy